Triptolide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Triptolide
Accession Number
DB12025
Type
Small Molecule
Groups
Investigational
Description

Triptolide has been used in trials studying the treatment of HIV, Crohn's Disease, Intestinal Diseases, Gastrointestinal Diseases, and Digestive System Diseases, among others.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
19ALD1S53J
CAS number
38748-32-2
Weight
Average: 360.406
Monoisotopic: 360.157288493
Chemical Formula
C20H24O6
InChI Key
DFBIRQPKNDILPW-CIVMWXNOSA-N
InChI
InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1
IUPAC Name
(1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-(propan-2-yl)-3,6,10,16-tetraoxaheptacyclo[11.7.0.0^{2,4}.0^{2,9}.0^{5,7}.0^{9,11}.0^{14,18}]icos-14(18)-en-17-one
SMILES
CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Triptolide.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Triptolide is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Triptolide is combined with 5-androstenedione.Experimental, Illicit
AbciximabTriptolide may increase the anticoagulant activities of Abciximab.Approved
AcebutololTriptolide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Triptolide is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Triptolide is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolTriptolide may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Triptolide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Triptolide.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Triptolide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Triptolide is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Alendronic acid.Approved
AliskirenTriptolide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Alminoprofen.Experimental
AlprenololTriptolide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Triptolide.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Amcinonide.Approved
AmilorideTriptolide may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Triptolide is combined with Aminosalicylic Acid.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Triptolide.Approved, Investigational, Withdrawn
AncrodTriptolide may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Triptolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Triptolide is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Triptolide is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Triptolide is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Triptolide.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Triptolide is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Triptolide is combined with Antipyrine.Approved, Investigational
Antithrombin III humanTriptolide may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Triptolide is combined with Antrafenine.Approved
ApixabanTriptolide may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Triptolide is combined with Apocynin.Investigational
ApramycinTriptolide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Triptolide.Approved, Investigational
ArbekacinTriptolide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTriptolide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTriptolide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTriptolide may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineTriptolide may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Triptolide is combined with Atamestane.Investigational
AtenololTriptolide may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Triptolide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Triptolide.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Triptolide is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Triptolide.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Triptolide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Triptolide is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Triptolide is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Triptolide is combined with Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Triptolide.Investigational
BecaplerminTriptolide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Triptolide is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTriptolide may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTriptolide may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Triptolide is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Triptolide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Triptolide is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Triptolide.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Triptolide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Triptolide is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Triptolide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Betamethasone.Approved, Vet Approved
BetaxololTriptolide may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Triptolide.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Triptolide.Approved, Investigational
BevantololTriptolide may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Triptolide is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Triptolide.Approved, Investigational
BisoprololTriptolide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTriptolide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTriptolide may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Triptolide is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Triptolide is combined with Bucillamine.Investigational
BucindololTriptolide may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Triptolide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Triptolide is combined with Bufexamac.Approved, Experimental
BufuralolTriptolide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Triptolide.Approved
BupranololTriptolide may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Triptolide.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Triptolide.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Triptolide.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Triptolide is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Triptolide is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Triptolide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Triptolide is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Triptolide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTriptolide may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Triptolide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Triptolide is combined with Celecoxib.Approved, Investigational
CeliprololTriptolide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTriptolide may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Triptolide.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Triptolide.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Triptolide is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Triptolide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Triptolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Triptolide is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Triptolide is combined with Cimicoxib.Investigational
CinoxacinTriptolide may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Triptolide is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Triptolide is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Triptolide is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Triptolide is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Triptolide.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Triptolide.Vet Approved
CloranololTriptolide may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Triptolide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ColesevelamColesevelam can cause a decrease in the absorption of Triptolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Triptolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Triptolide is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Triptolide is combined with Cortisone acetate.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Triptolide is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Triptolide.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Triptolide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Triptolide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Triptolide.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Triptolide.Experimental
Dabigatran etexilateTriptolide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTriptolide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTriptolide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanTriptolide may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Triptolide is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Triptolide is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Delapril.Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Triptolide.Approved
DesipramineTriptolide may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinTriptolide may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Triptolide.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Triptolide is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Triptolide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Triptolide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Triptolide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Triptolide is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Triptolide.Approved, Investigational
DextranTriptolide may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinTriptolide may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Triptolide is combined with Dibotermin alfa.Approved, Investigational
DicoumarolTriptolide may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Triptolide is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Triptolide is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Triptolide is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Triptolide.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Triptolide.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Triptolide.Approved
DihydrostreptomycinTriptolide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Triptolide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Triptolide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Triptolide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Triptolide.Approved, Investigational
DrospirenoneTriptolide may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Triptolide is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Triptolide.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Triptolide.Investigational
Edetic AcidTriptolide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTriptolide may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Triptolide is combined with Enalaprilat.Approved
EnoxacinTriptolide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTriptolide may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Triptolide.Experimental
EpanololTriptolide may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Triptolide.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Triptolide.Experimental
EplerenoneTriptolide may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Triptolide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Triptolide.Approved
EquileninThe risk or severity of adverse effects can be increased when Triptolide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Triptolide is combined with Equilin.Approved
EsatenololTriptolide may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololTriptolide may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Triptolide is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Triptolide.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Triptolide is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Triptolide is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTriptolide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Triptolide is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Triptolide.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Triptolide is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Triptolide.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Triptolide.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Triptolide.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Triptolide.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Triptolide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Triptolide.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Triptolide is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Feprazone.Experimental
Ferulic acidTriptolide may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Triptolide.Approved, Investigational
FingolimodTriptolide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinTriptolide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Triptolide.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fludrocortisone.Approved, Investigational
FluindioneTriptolide may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineTriptolide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Triptolide.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Triptolide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Triptolide.Approved, Nutraceutical, Vet Approved
FondaparinuxTriptolide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Triptolide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Triptolide is combined with Formestane.Approved, Investigational, Withdrawn
FramycetinTriptolide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
G17DTThe risk or severity of adverse effects can be increased when Triptolide is combined with G17DT.Investigational
GabexateTriptolide may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTriptolide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTriptolide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Triptolide.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Triptolide.Approved, Withdrawn
GemifloxacinTriptolide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTriptolide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTriptolide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATriptolide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The risk or severity of adverse effects can be increased when Triptolide is combined with GI-5005.Investigational
GinsengThe risk or severity of adverse effects can be increased when Triptolide is combined with Ginseng.Approved, Investigational, Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Triptolide.Experimental
GrepafloxacinTriptolide may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Triptolide is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Triptolide is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Triptolide is combined with HE3286.Investigational
HeparinTriptolide may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Triptolide is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Triptolide is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Triptolide is combined with Higenamine.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Triptolide is combined with Human rabies virus immune globulin.Approved
HydralazineTriptolide may decrease the antihypertensive activities of Hydralazine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Triptolide.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Triptolide is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Triptolide is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Triptolide.Approved, Investigational
Hygromycin BTriptolide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Triptolide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Triptolide.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Triptolide is combined with Icosapent.Approved, Nutraceutical
IdraparinuxTriptolide may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Triptolide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Triptolide is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Triptolide.Approved
IndenololTriptolide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Triptolide is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Triptolide is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Triptolide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Triptolide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Triptolide is combined with INGN 225.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Triptolide.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Triptolide.Approved, Investigational
IsepamicinTriptolide may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Triptolide.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Triptolide is combined with Istaroxime.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Triptolide is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KanamycinTriptolide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Triptolide.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Ketoprofen.Approved, Vet Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Triptolide.Experimental
LandiololTriptolide may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Triptolide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Triptolide is combined with Leflunomide.Approved, Investigational
LepirudinTriptolide may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTriptolide may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololTriptolide may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololTriptolide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTriptolide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Triptolide.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Triptolide is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Triptolide.Experimental
LomefloxacinTriptolide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Triptolide is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Triptolide is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Triptolide is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Triptolide.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Triptolide.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Triptolide is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Triptolide.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Triptolide is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Triptolide.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Triptolide is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Mefenamic acid.Approved
MelagatranTriptolide may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Triptolide is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Triptolide is combined with Meloxicam.Approved, Vet Approved
MepindololTriptolide may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Triptolide is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Triptolide.Approved, Investigational, Withdrawn
MethimazoleThe risk or severity of adverse effects can be increased when Triptolide is combined with Methimazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Triptolide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Triptolide.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Triptolide.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Triptolide.Experimental
MetipranololTriptolide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Triptolide.Approved
MicronomicinTriptolide may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Triptolide.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Triptolide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Triptolide is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Triptolide.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Triptolide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triptolide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Nabumetone.Approved
NadololTriptolide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTriptolide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatTriptolide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Triptolide.Approved
Nalidixic AcidTriptolide may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Triptolide is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Triptolide is combined with NCX 1022.Investigational
NeamineTriptolide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTriptolide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTriptolide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Triptolide is combined with Nepafenac.Approved, Investigational
NetilmicinTriptolide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Triptolide is combined with Niflumic Acid.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Triptolide is combined with Nitroaspirin.Investigational
NorfloxacinTriptolide may increase the neuroexcitatory activities of Norfloxacin.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Triptolide.Approved, Investigational
OfloxacinTriptolide may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Triptolide.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Triptolide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triptolide.Approved
OlsalazineTriptolide may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Triptolide is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Triptolide is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Triptolide.Vet Approved
OtamixabanTriptolide may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Triptolide.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Triptolide is combined with Oxaprozin.Approved
Oxolinic acidTriptolide may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTriptolide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Triptolide.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Triptolide.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Triptolide is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Triptolide is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Triptolide is combined with Parecoxib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Parthenolide.Approved, Investigational
PazufloxacinTriptolide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTriptolide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTriptolide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTriptolide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateTriptolide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Triptolide.Experimental
PhenindioneTriptolide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTriptolide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Triptolide.Approved, Investigational
PindololTriptolide may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidTriptolide may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Triptolide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Triptolide.Approved, Investigational
Piromidic acidTriptolide may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Triptolide is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Triptolide is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorTriptolide may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTriptolide may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Triptolide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Triptolide is combined with Pomalidomide.Approved
Potassium CitrateTriptolide may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololTriptolide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Triptolide.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Triptolide is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Triptolide is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Triptolide.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Triptolide can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Triptolide is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Triptolide.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Triptolide.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Triptolide.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Triptolide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Triptolide.Vet Approved
Protein CTriptolide may increase the anticoagulant activities of Protein C.Approved
Protein S humanTriptolide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTriptolide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTriptolide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Triptolide.Investigational
PuromycinTriptolide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Triptolide.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Triptolide is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Triptolide.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Triptolide is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Triptolide is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinTriptolide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTriptolide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Triptolide is combined with Rindopepimut.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Triptolide is combined with Risedronate.Approved, Investigational
RivaroxabanTriptolide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Triptolide is combined with Rofecoxib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Triptolide.Approved
RosoxacinTriptolide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Triptolide is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Triptolide is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinTriptolide may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Triptolide.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Triptolide.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Triptolide is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of adverse effects can be increased when Triptolide is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Triptolide is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Triptolide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Triptolide.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Triptolide is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Triptolide is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Triptolide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Triptolide is combined with Serrapeptase.Investigational
SisomicinTriptolide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTriptolide may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SotalolTriptolide may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinTriptolide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Spirapril.Approved
SRP 299The risk or severity of adverse effects can be increased when Triptolide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Triptolide.Investigational
StreptomycinTriptolide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Triptolide is combined with Sulfasalazine.Approved
SulodexideTriptolide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Triptolide.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Suxibuzone.Experimental
TacrolimusTacrolimus may increase the immunosuppressive activities of Triptolide.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Triptolide.Approved
TalinololTriptolide may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Triptolide.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Triptolide.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Triptolide.Approved
TecemotideThe risk or severity of adverse effects can be increased when Triptolide is combined with Tecemotide.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Triptolide is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Triptolide is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Triptolide.Approved, Investigational
TemafloxacinTriptolide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Triptolide is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Triptolide is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Triptolide is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Triptolide.Vet Approved
TerbutalineTriptolide may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Triptolide.Approved
TertatololTriptolide may decrease the antihypertensive activities of Tertatolol.Experimental
TetrandrineThe risk or severity of adverse effects can be increased when Triptolide is combined with Tetrandrine.Experimental
TG4010The risk or severity of adverse effects can be increased when Triptolide is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTriptolide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Triptolide is combined with Tinoridine.Investigational
TipiracilThe therapeutic efficacy of Triptolide can be decreased when used in combination with Tipiracil.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Triptolide is combined with Tixocortol.Approved, Withdrawn
TobramycinTriptolide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibTriptolide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Triptolide is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Triptolide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Trandolapril.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Triptolide.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Triptolide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Triptolide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTriptolide may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Triptolide is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Triptolide.Approved, Vet Approved
TrovafloxacinTriptolide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTriptolide may increase the anticoagulant activities of Troxerutin.Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Triptolide is combined with Typhoid Vaccine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Triptolide is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Triptolide.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Triptolide is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Triptolide.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Triptolide is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
WarfarinTriptolide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTriptolide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Triptolide is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triptolide.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Triptolide is combined with Zidovudine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Triptolide.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Triptolide is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Triptolide.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C09204
PubChem Compound
107985
PubChem Substance
347828340
ChemSpider
97099
BindingDB
50241049
ChEBI
9747
ChEMBL
CHEMBL463763
Wikipedia
Triptolide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV)1
2, 3Unknown StatusTreatmentCrohn's Disease (CD) / Digestive System Diseases / Gastrointestinal Diseases / Inflammatory Bowel Diseases (IBD) / Intestinal Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.886 mg/mLALOGPS
logP1.22ALOGPS
logP1.33ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)12.54ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area84.12 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity87.26 m3·mol-1ChemAxon
Polarizability37.14 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0429000000-1df7fd8b89c25073ab2d

Taxonomy

Description
This compound belongs to the class of organic compounds known as oxepanes. These are compounds containing an oxepane ring, which is a seven-member saturated aliphatic heterocycle with one oxygen and six carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxepanes
Sub Class
Not Available
Direct Parent
Oxepanes
Alternative Parents
Butenolides / Enoate esters / Secondary alcohols / Lactones / Cyclic alcohols and derivatives / Oxacyclic compounds / Monocarboxylic acids and derivatives / Epoxides / Dialkyl ethers / Organic oxides
show 2 more
Substituents
Oxepane / 2-furanone / Cyclic alcohol / Dihydrofuran / Alpha,beta-unsaturated carboxylic ester / Enoate ester / Carboxylic acid ester / Lactone / Secondary alcohol / Monocarboxylic acid or derivatives
show 12 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
oxacycle (CHEBI:9747) / Diterpenoids (C20) (C09204)

Drug created on October 20, 2016 15:12 / Updated on August 02, 2018 06:32